Compare IPAR & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | SLNO |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 1988 | 2014 |
| Metric | IPAR | SLNO |
|---|---|---|
| Price | $82.73 | $51.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $128.20 | $110.90 |
| AVG Volume (30 Days) | 286.0K | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | ★ 9.68 | N/A |
| EPS | ★ 5.13 | N/A |
| Revenue | ★ $1,463,838,000.00 | $98,675,000.00 |
| Revenue This Year | $3.42 | N/A |
| Revenue Next Year | $1.53 | $155.86 |
| P/E Ratio | $16.15 | ★ N/A |
| Revenue Growth | ★ 3.12 | N/A |
| 52 Week Low | $77.21 | $41.50 |
| 52 Week High | $148.15 | $90.32 |
| Indicator | IPAR | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 48.33 |
| Support Level | $79.50 | $47.80 |
| Resistance Level | $82.10 | $53.10 |
| Average True Range (ATR) | 2.76 | 2.47 |
| MACD | 0.54 | 1.09 |
| Stochastic Oscillator | 53.57 | 79.48 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations.. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.